NEO:CYBN - Post Discussion
Cybin Inc
> Cybin Inc. Announces Completion of 20th Preclinical Study
Post by
TrojanHorse82 on Mar 29, 2021 12:31am
Cybin Inc. Announces Completion of 20th Preclinical Study
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both in-vitro and in-vivo. Based on proprietary Cybin technologies, more than 20 definitive research studies designed by the company’s scientists were completed in record time.
Be the first to comment on this post